Program
Anti-ADAM9/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C0979
Its studies are led by BeOne Medicines.
Furthest: phase 1, since Feb 11, 20261 company-led study, 1 open or runningNext primary completion: Apr 30, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Apr 30, 2029phase 1 · NCT07414836 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2026First study: phase 1 study in Advanced Solid TumorFirst studyNCT07414836 · 84 planned · United States, Australia, China and more
Ahead
- Apr 30, 2029Primary completion: phase 1 study in Advanced Solid TumorNCT07414836
TargetBeta
ADAM9 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) a disintegrin and metalloproteinase domain 9 (ADAM9), ”NCIt, by rule
Other programs on ADAM9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028rule | MacroGenics | phase 1 | 1 |
| Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317rule | dualitybio-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07414836Advanced Solid Tumor · United States, Australia, China and more | 1 | Recruiting | Apr 30, 2029 | 84 |
How it is read
Names in the registry
- “BG-C0979”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.